or Try an Advanced Search...

    Technical Analysis for LPCN - Lipocine Inc.

    Grade Last Price % Change Price Change
    B 6.08 9.75% 0.54
    LPCN closed up 9.75 percent on Friday, November 1, 2024, on 2.38 times normal volume.
    Earnings due: Nov 6
    *** please verify all earnings dates ***
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Up Up Up
    Historical LPCN trend table...
    Date Alert Name Type % Chg
    MACD Bullish Signal Line Cross Bullish 0.00%
    Pocket Pivot Bullish Swing Setup 0.00%
    Bollinger Band Squeeze Range Contraction 0.00%
    BB Squeeze + Upper Band Touch Range Contraction 0.00%
    Above Upper BB Strength 0.00%
    Gapped Up Strength 0.00%
    Upper Bollinger Band Touch Strength 0.00%
    MACD Bearish Signal Line Cross Bearish 9.75%
    Bollinger Band Squeeze Range Contraction 9.75%
    Bollinger Band Squeeze Range Contraction 12.18%
    Older End-of-Day Signals for LPCN ...

       Recent Intraday Alerts

    Alert Time
    Possible Pocket Pivot 1 day ago
    Up 10% 1 day ago
    Rose Above Upper Bollinger Band 1 day ago
    Up 5% 1 day ago
    Upper Bollinger Band Resistance 1 day ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    LPCN Chart by TradingView
    Basic chart:

    Profile

    Lipocine Inc. Description

    Lipocine Inc., a specialty pharmaceutical company, is engaged in the development of pharmaceutical products in the areas of men's and women's health. The company offers a portfolio of proprietary product candidates that are used to produce pharmacokinetic characteristics; facilitate lower dosing requirements and bypass first-pass metabolism; reduce side effects; and eliminate gastrointestinal interactions that limit bioavailability. Its product candidates for men's health include LPCN 1021, an oral product candidate, which is in Phase III clinical trials; and LPCN 1111, an oral product candidate that is in Phase I/II clinical trials for the treatment of testosterone replacement therapy. The company's product candidates for women's health comprise LPCN 1107, which is in Phase I/II clinical trials for the prevention of preterm birth. Lipocine Inc. was founded in 1997 and is headquartered in Salt Lake City, Utah.

    Classification
    Sector: Healthcare
    Industry: Drug Manufacturers - Specialty & Generic
    Keywords: Pharmaceutical Alcohol Pharmaceutical Products Gastrointestinal Clinical Research Clinical Trial Metabolism Bypass Ketones Testosterone Androstanes Preterm Birth

    Is LPCN a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Oct 31 Lipocine Announces Distribution and License Agreement with SPC Korea to Commercialize TLANDO® in South Korea
    Oct 10 Lipocine Announces Positive Oral Brexanolone Quantitative EEG Results
    Oct 9 Lipocine signs supply and distribution agreement with Pharmalink for Tlando
    Oct 8 Lipocine Announces Supply and Distribution Agreement with Pharmalink to Commercialize TLANDO® in the Gulf Cooperation Council (GCC) Countries
    Oct 2 Lipocine to Host Virtual KOL Event on LPCN 2401 for Improved Body Composition in Obesity Management on October 16, 2024
    Sep 30 Lipocine to Present at H.C. Wainwright 8th Annual MASH Investor Conference
    Sep 5 Lipocine Announces Phase 2 Data on LPCN 2401 to be Presented at ObesityWeek®
    Aug 27 Lipocine to Present at H.C. Wainwright 26th Annual Global Investment Conference
    Aug 8 Lipocine GAAP EPS of -$0.56 beats by $0.22, revenue of $0.09M misses by $0.2M
    Aug 8 Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2024
    See more LPCN news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 11.79
    52 Week Low 2.35
    Average Volume 29,916
    200-Day Moving Average 5.19
    50-Day Moving Average 4.67
    20-Day Moving Average 5.38
    10-Day Moving Average 5.62
    Average True Range 0.39
    RSI (14) 70.33
    ADX 39.42
    +DI 29.55
    -DI 9.43
    Chandelier Exit (Long, 3 ATRs) 4.95
    Chandelier Exit (Short, 3 ATRs) 5.58
    Upper Bollinger Bands 5.94
    Lower Bollinger Band 4.82
    Percent B (%b) 1.12
    BandWidth 20.85
    MACD Line 0.28
    MACD Signal Line 0.26
    MACD Histogram 0.0221
    Fundamentals Value
    Market Cap 32.32 Million
    Num Shares 5.32 Million
    EPS -3.21
    Price-to-Earnings (P/E) Ratio -1.89
    Price-to-Sales 2.36
    Price-to-Book 0.95
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 6.97
    Resistance 3 (R3) 6.88 6.51 6.82
    Resistance 2 (R2) 6.51 6.28 6.55 6.77
    Resistance 1 (R1) 6.29 6.14 6.40 6.38 6.72
    Pivot Point 5.92 5.92 5.97 5.96 5.92
    Support 1 (S1) 5.70 5.69 5.81 5.79 5.44
    Support 2 (S2) 5.33 5.55 5.37 5.39
    Support 3 (S3) 5.11 5.33 5.34
    Support 4 (S4) 5.20